NASDAQ: ELVNEnliven Therapeutics Inc Stock
$42.36-3.77 (-8.17%)
Updated Jun 15, 2026
ELVN Price
$42.36
Fair Value Price
$1.74
Market Cap
$2.58B
52 Week Low
$14.79
52 Week High
$48.53
P/E
-25.37x
P/B
5.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$98.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$65M
Beta
1.1
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ELVN Overview
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ELVN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ELVN
Ranked#116 of 462
Ranked#116 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important ELVN news, forecast changes, insider trades & much more!
ELVN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ELVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELVN ($42.36) is overvalued by 2,336.92% relative to our estimate of its Fair Value price of $1.74 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ELVN ($42.36) is not significantly undervalued (2,336.92%) relative to our estimate of its Fair Value price of $1.74 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ELVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ELVN due diligence checks available for Premium users.
Valuation
ELVN fair value
Fair Value of ELVN stock based on Discounted Cash Flow (DCF)
Price
$42.36
Fair Value
$1.74
Overvalued by
2,336.92%
ELVN ($42.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ELVN ($42.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ELVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-25.37x
Industry
16.41x
Market
14.3x
ELVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.69x
Industry
4.89x
ELVN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELVN's financial health
Profit margin
Revenue
$0.0
Net Income
-$23.6M
Profit Margin
0%
ELVN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$464.9M
Liabilities
$11.5M
Debt to equity
0.03
ELVN's short-term assets ($463.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELVN's short-term assets ($463.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELVN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ELVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.3M
Investing
$42.5M
Financing
$10.1M
ELVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELVN vs Biotech Stocks
Enliven Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.